Navigation Links
Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Date:8/19/2007

ANNAPOLIS, Md., Aug. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing and commercializing medical countermeasures against biological and chemical threats, announced today that proceedings have been initiated with the Delaware Chancery Court to affirm the validity of the merger between Healthcare Acquisition Corp. and PharmAthene.

"We hope that the Court of Chancery will determine that the Merger was validly approved and consummated so that PharmAthene may, in accordance with the desires of an overwhelming majority of its stockholders, make use of the funds held in escrow towards the furtherance of its business plan. We remind you that the action initiated by our shareholder is intended to seek affirmation from the court of the validity of the merger, and should not be interpreted by PharmAthene shareholders as a challenge to the merger," said David P. Wright, President and Chief Executive Officer of PharmAthene.

The certificate of merger was filed on August 3, 2007. Shares of PharmAthene began trading on the American Stock Exchange on August 7, 2007, under the symbol 'PIP' and 'PIP-WT' for the company's warrants.

Additional Information

HAQ AND PHARMATHENE CLAIM THE PROTECTION OF THE SAFE HARBOR FOR "FORWARD- LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF HAQ AND PHARMATHENE REGARDING, AMONG OTHER THINGS, THE POTENTIAL DETERMINATIONS BY A COURT OF CHANCERY IN DELAWARE AS TO THE VALIDITY OF THE APPROVAL OF THE MERGER, WHICH CANNOT BE PREDICTED WITH CERTAINTY. NO ASSURANCES CAN BE GIVEN THAT OTHER PARTIES WILL NOT OPPOSE CONFIRMATION OF SUCH VALIDITY. IN THE EVENT THAT THE DELAWARE COURT OF CHANCERY DOES NOT AFFIRM SUCH VALIDITY, PHARMATHENE COULD BE REQUIRED TO LIQUIDATE ANY FUNDS THEN HELD IN TRUST. THIS PROCEEDING WILL NOT AFFECT THE DISTRIBUTION OF THE TRUST FUND TO STOCKHOLDERS WHO ELECTED CONVERSION.

About PharmAthene, Inc.

PharmAthene is a biodefense company formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim(TM) and Protexia(R). For more information on PharmAthene, please visit its website at http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene

Copyright©2007 PR Newswire.

Related biology technology :

1. Study affirms information technology-productivity link
2. Wisconsin court affirms damages in Innogenetics, Abbott patent case
3. Technology and mergers: Getting the strategic applications
4. AT&T - BellSouth merger: Revestiture continues
5. CDW names VP to handle Berbee merger
6. Some great insights into the current Mergers & Acquisitions Market
7. Merges merger is the crux of shareholder lawsuits
8. Technology grants, Bone Care merger
9. FTC has fast-tracked Bone Care merger
10. Merge eFilm corporate merger with Canadian firm moves ahead
11. Drug innovation beats marketing, patents and mergers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... March 30, 2020 , ... ... developer Reliant Immune Diagnostics (RID), formed earlier this year to bring telehealth to ... creating in-home tests for COVID-19. Company officials are currently?awaiting an Emergency Use Authorization ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... laboratory located centrally in the midwest for high-quality, quick-turn, board-certified reporting. In ... highly motivated, independent, professional team that is focused on incredible quality, turnaround ...
(Date:3/13/2020)... ... March 12, 2020 , ... Today, DuPont Nutrition & ... Center (APC), a pioneer in the field of microbiome science, which focuses on ... in human health, based at University College Cork and Teagasc Moorepark. , Representatives ...
(Date:3/10/2020)... ... 10, 2020 , ... Lifecycle Biotechnologies announced today that is has ... be used as a biopharmaceutical and biotechnology production and development campus. Lifecycle is currently ... as its production and development hub. The company expects to relocate from Fort Worth, ...
Breaking Biology Technology:
(Date:3/20/2020)... , ... March 20, 2020 , ... OUHSC and Pure ... for the COVID-19 virus. The scientific team is led by William Hildebrand, Ph.D., whose ... will be working with Pure MHC, part of a family of biotechnology companies formed, ...
(Date:3/19/2020)... ... , ... The former Jason "Furious" Styles of "Boyz n the Hood" (1991), ... The TV program highlights a large variety of subjects that have an impact on ... a dive into the world of applied academics. The episode will cover education in ...
(Date:3/13/2020)... ... March 13, 2020 , ... Acumed LLC today announced ... exclusive distributor of the Louisville-based company’s orthobiologics portfolio. Under the terms of the ... Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium phosphate-based biocement (Fortera). Vivorte will ...
Breaking Biology News(10 mins):